You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEfavirenz
Accession NumberDB00625  (APRD00059, DB07709)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEfavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Structure
Thumb
Synonyms
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
Efavirenz
Éfavirenz
Efavirenzum
External Identifiers
  • DMP 266
  • L 743726
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-efavirenztablet600 mgoralAuro Pharma Inc2014-03-03Not applicableCanada
Mylan-efavirenztablet600 mgoralMylan Pharmaceuticals Ulc2013-07-30Not applicableCanada
StocrinOral solution30 mg/mlOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule, hard50 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinFilm-coated tablet600 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule, hard100 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinFilm-coated tablet50 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule, hard200 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinFilm-coated tablet200 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule, hard200 mgOral useMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
SustivaCapsule, hard200 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
Sustivacapsule, gelatin coated50 mg/1oralBristol Myers Squibb Pharma Company1998-09-17Not applicableUs
SustivaCapsule, hard50 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaFilm-coated tablet600 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
Sustivacapsule, gelatin coated200 mg/1oralBristol Myers Squibb Pharma Company1998-09-17Not applicableUs
SustivaCapsule, hard100 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaFilm-coated tablet600 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
Sustivatablet, film coated600 mg/1oralBristol Myers Squibb Pharma Company2002-01-02Not applicableUs
SustivaCapsule, hard200 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaFilm-coated tablet600 mgOral useBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
Sustivatablet, film coated600 mg/1oralPhysicians Total Care, Inc.2012-10-11Not applicableUs
Sustiva 100mgcapsule100 mgoralBristol Myers Squibb Canada1999-03-252008-03-27Canada
Sustiva 200mgcapsule200 mgoralBristol Myers Squibb Canada1999-03-25Not applicableCanada
Sustiva 50mgcapsule50 mgoralBristol Myers Squibb Canada1999-03-25Not applicableCanada
Sustiva Tabletstablet600 mgoralBristol Myers Squibb Canada2002-11-05Not applicableCanada
Teva-efavirenztablet600 mgoralTeva Canada Limited2013-07-30Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
E.FMcNeil & Argus
EfavirCipla
EfavirenzAspen Pharmacare
EfcureEmcure Pharmaceuticals
EffervenRanbaxy Laboratories
EstivaHetero
EvirenzAlkem Laboratories
StocrinMerck & Co.
ViranzAurobindo Pharma
Brand mixtures
NameLabellerIngredients
AtriplaBristol Myers Squibb & Gilead Sciences, Llc
SaltsNot Available
Categories
UNIIJE6H2O27P8
CAS number154598-52-4
WeightAverage: 315.675
Monoisotopic: 315.027390859
Chemical FormulaC14H9ClF3NO2
InChI KeyInChIKey=XPOQHMRABVBWPR-ZDUSSCGKSA-N
InChI
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
IUPAC Name
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one
SMILES
FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazines
Sub ClassNot Available
Direct ParentBenzoxazines
Alternative Parents
Substituents
  • Benzoxazine
  • Benzenoid
  • Ynone
  • Aryl halide
  • Aryl chloride
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use in combination treatment of HIV infection (AIDS)
PharmacodynamicsEfavirenz (dideoxyinosine, ddI) is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.
Mechanism of actionSimilar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding99.5-99.75%
Metabolism

Efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1.

Route of eliminationNearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites.
Half life40-55 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategorySMPDB ID
Efavirenz Action PathwayDrug actionSMP00740
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9182
Caco-2 permeable+0.5553
P-glycoprotein substrateNon-substrate0.7617
P-glycoprotein inhibitor INon-inhibitor0.7451
P-glycoprotein inhibitor IINon-inhibitor0.9557
Renal organic cation transporterNon-inhibitor0.9157
CYP450 2C9 substrateNon-substrate0.8033
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6037
CYP450 1A2 substrateInhibitor0.6996
CYP450 2C9 inhibitorNon-inhibitor0.6975
CYP450 2D6 inhibitorNon-inhibitor0.8699
CYP450 2C19 inhibitorNon-inhibitor0.5291
CYP450 3A4 inhibitorNon-inhibitor0.7577
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6705
Ames testNon AMES toxic0.6991
CarcinogenicityNon-carcinogens0.8997
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9617
hERG inhibition (predictor II)Non-inhibitor0.9098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb co
  • Bristol myers squibb pharma co
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tablet, film coatedoral
Capsule, hardOral use100 mg
Capsule, hardOral use200 mg
Capsule, hardOral use50 mg
Film-coated tabletOral use200 mg
Film-coated tabletOral use50 mg
Film-coated tabletOral use600 mg
Oral solutionOral use30 mg/ml
Capsule, gelatin coatedoral200 mg/1
Capsule, gelatin coatedoral50 mg/1
Tablet, film coatedoral600 mg/1
Capsuleoral100 mg
Capsuleoral200 mg
Capsuleoral50 mg
Tabletoral600 mg
Prices
Unit descriptionCostUnit
Sustiva 600 mg tablet21.68USD tablet
Sustiva 200 mg capsule7.37USD capsule
Sustiva 100 mg capsule3.34USD capsule
Sustiva 50 mg capsule1.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2101572 No2001-08-282013-07-29Canada
CA2279198 No2009-04-142018-02-02Canada
US5811423 No1992-08-072012-08-07Us
US5814639 Yes1996-03-292016-03-29Us
US5914331 Yes1998-01-022018-01-02Us
US5922695 Yes1998-01-252018-01-25Us
US5935946 Yes1998-01-252018-01-25Us
US5977089 Yes1998-01-252018-01-25Us
US6043230 Yes1998-01-252018-01-25Us
US6238695 Yes1999-10-062019-10-06Us
US6555133 Yes1999-10-062019-10-06Us
US6639071 Yes1998-08-142018-08-14Us
US6642245 Yes2001-05-042021-05-04Us
US6703396 Yes2001-09-092021-09-09Us
US6939964 Yes1998-07-202018-07-20Us
US8592397 No2004-01-132024-01-13Us
US8598185 No2008-05-012028-05-01Us
US8716264 No2004-01-132024-01-13Us
US9018192 No2006-06-132026-06-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point139-141 °CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00855 mg/mLALOGPS
logP3.89ALOGPS
logP4.46ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)12.52ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.34 m3·mol-1ChemAxon
Polarizability26.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

John Doney, “Amorphous efavirenz and the production thereof.” U.S. Patent US20070026073, issued February 01, 2007.

US20070026073
General References
  1. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5. Epub 2002 Oct 17. [PubMed:12386343 ]
External Links
ATC CodesJ05AR06J05AG03J05AR11
AHFS Codes
  • 08:18.08.16
PDB EntriesNot Available
FDA labelDownload (154 KB)
MSDSDownload (57.6 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Efavirenz.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Efavirenz.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Efavirenz.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Efavirenz.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Efavirenz.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Efavirenz.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Efavirenz.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Efavirenz.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Efavirenz.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Efavirenz.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Efavirenz.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Efavirenz.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Efavirenz.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Efavirenz.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Efavirenz.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Efavirenz.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Efavirenz.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Efavirenz.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Efavirenz.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Efavirenz.
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Efavirenz.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Efavirenz.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Efavirenz.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Efavirenz.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Efavirenz.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Efavirenz.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Efavirenz.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Efavirenz.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Efavirenz.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Efavirenz.
AmiodaroneThe metabolism of Efavirenz can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Efavirenz.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Efavirenz.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Efavirenz.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Efavirenz.
AmodiaquineEfavirenz may increase the hepatotoxic activities of Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Efavirenz.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Efavirenz.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Efavirenz.
AmrinoneThe serum concentration of Amrinone can be decreased when it is combined with Efavirenz.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Efavirenz.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Efavirenz.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Efavirenz.
AprepitantThe serum concentration of Efavirenz can be increased when it is combined with Aprepitant.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Efavirenz.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Efavirenz.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Efavirenz.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Efavirenz.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Efavirenz.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Efavirenz.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Efavirenz.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Efavirenz.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Efavirenz.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Efavirenz.
AtazanavirThe metabolism of Efavirenz can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Efavirenz can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Efavirenz.
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Efavirenz.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Efavirenz.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Efavirenz.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Efavirenz.
AzelastineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Efavirenz.
AzelnidipineThe serum concentration of Azelnidipine can be decreased when it is combined with Efavirenz.
AzimilideThe serum concentration of Azimilide can be decreased when it is combined with Efavirenz.
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Efavirenz.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Efavirenz.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Efavirenz.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Efavirenz.
BarnidipineThe serum concentration of Barnidipine can be decreased when it is combined with Efavirenz.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Efavirenz.
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Efavirenz.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Efavirenz.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Efavirenz.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Efavirenz.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Efavirenz.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Efavirenz.
BepridilThe serum concentration of Bepridil can be decreased when it is combined with Efavirenz.
BeraprostThe metabolism of Beraprost can be decreased when combined with Efavirenz.
BexaroteneThe serum concentration of Efavirenz can be decreased when it is combined with Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Efavirenz.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Efavirenz.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Efavirenz.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Efavirenz.
BoceprevirThe metabolism of Efavirenz can be decreased when combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Efavirenz.
BortezomibThe metabolism of Efavirenz can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Efavirenz can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Efavirenz.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Efavirenz.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Efavirenz.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Efavirenz.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Efavirenz.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
BrimonidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Brimonidine.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Efavirenz.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Efavirenz.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Efavirenz.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Efavirenz.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Efavirenz.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Efavirenz.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Efavirenz.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Efavirenz.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Efavirenz.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Efavirenz.
BuprenorphineThe serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Efavirenz.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Efavirenz.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Efavirenz.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Efavirenz.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Efavirenz.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Efavirenz.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Efavirenz.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Efavirenz.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Efavirenz.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Efavirenz.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Efavirenz.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Efavirenz.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Efavirenz.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Efavirenz.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Efavirenz.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.
CandesartanThe metabolism of Candesartan can be decreased when combined with Efavirenz.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Efavirenz.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Efavirenz.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Efavirenz.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Efavirenz.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Efavirenz.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Efavirenz.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Efavirenz.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Efavirenz.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Efavirenz.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Efavirenz.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Efavirenz.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Efavirenz.
CeritinibThe serum concentration of Efavirenz can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Efavirenz.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Efavirenz.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Efavirenz.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Efavirenz.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Efavirenz.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Efavirenz.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Efavirenz.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Efavirenz.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Efavirenz.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Efavirenz.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Efavirenz.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Efavirenz.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Efavirenz.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Efavirenz.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efavirenz.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Efavirenz.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Efavirenz.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Efavirenz.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Efavirenz.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Efavirenz.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Efavirenz.
CilnidipineThe serum concentration of Cilnidipine can be decreased when it is combined with Efavirenz.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Efavirenz.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Efavirenz.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Efavirenz.
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Efavirenz.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Efavirenz.
CitalopramThe risk or severity of adverse effects can be increased when Efavirenz is combined with Citalopram.
CitalopramThe metabolism of Efavirenz can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Efavirenz.
ClarithromycinThe metabolism of Efavirenz can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Efavirenz can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clemastine.
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.
ClidiniumThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clidinium.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Efavirenz.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Efavirenz.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Efavirenz.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Efavirenz.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Efavirenz.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Efavirenz.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Efavirenz.
ClomipramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clomipramine.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Efavirenz.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Efavirenz.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Efavirenz.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Efavirenz.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Efavirenz.
ClopidogrelThe metabolism of Efavirenz can be decreased when combined with Clopidogrel.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Efavirenz.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Efavirenz.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Efavirenz.
ClotrimazoleThe metabolism of Efavirenz can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Efavirenz.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Efavirenz.
CobicistatThe metabolism of Efavirenz can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Efavirenz.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Efavirenz.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Efavirenz.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Efavirenz.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Efavirenz.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Efavirenz.
ConivaptanThe serum concentration of Efavirenz can be increased when it is combined with Conivaptan.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Efavirenz.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Efavirenz.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Efavirenz.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Efavirenz.
CrizotinibThe metabolism of Efavirenz can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Cyclizine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Efavirenz.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Efavirenz.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Efavirenz.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.
CyclosporineThe metabolism of Efavirenz can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Efavirenz.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Efavirenz.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Efavirenz.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Efavirenz.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Efavirenz.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Efavirenz.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Efavirenz.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Efavirenz.
DapoxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dapoxetine.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Efavirenz.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Efavirenz.
DarodipineThe serum concentration of Darodipine can be decreased when it is combined with Efavirenz.
DarunavirThe serum concentration of Efavirenz can be increased when it is combined with Darunavir.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Efavirenz.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Efavirenz.
DasatinibThe serum concentration of Efavirenz can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Efavirenz.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Efavirenz.
DeferasiroxThe serum concentration of Efavirenz can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Efavirenz.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Efavirenz.
DelavirdineThe metabolism of Efavirenz can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Efavirenz.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Efavirenz.
DesipramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desloratadine.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Efavirenz.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Efavirenz.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Efavirenz.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Efavirenz.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Efavirenz.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efavirenz.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Efavirenz.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efavirenz.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Efavirenz.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Efavirenz.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Efavirenz.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Efavirenz.
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Efavirenz.
DifenoxinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Efavirenz.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Efavirenz.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Efavirenz.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efavirenz.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Efavirenz.
DihydroergotamineThe metabolism of Efavirenz can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efavirenz.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efavirenz.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Efavirenz.
DiltiazemThe metabolism of Efavirenz can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Efavirenz.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efavirenz.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Efavirenz.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Efavirenz.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Efavirenz.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Efavirenz.
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Efavirenz.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Efavirenz.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Efavirenz.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Efavirenz.
DopamineThe metabolism of Dopamine can be decreased when combined with Efavirenz.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Efavirenz.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Efavirenz.
DotarizineThe serum concentration of Dotarizine can be decreased when it is combined with Efavirenz.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Efavirenz.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Efavirenz.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Efavirenz.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Efavirenz.
DoxorubicinThe metabolism of Efavirenz can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Efavirenz can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
DoxylamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Efavirenz.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Efavirenz.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Efavirenz.
DronedaroneThe metabolism of Efavirenz can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Efavirenz.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Efavirenz.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Efavirenz.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Efavirenz.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Efavirenz.
EfonidipineThe serum concentration of Efonidipine can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Efavirenz.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Efavirenz.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Efavirenz.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Efavirenz.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Efavirenz.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Efavirenz.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Efavirenz.
EperisoneThe serum concentration of Eperisone can be decreased when it is combined with Efavirenz.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Efavirenz.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Efavirenz.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Efavirenz.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Efavirenz.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Efavirenz.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Efavirenz.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Efavirenz.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Efavirenz.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Efavirenz.
ErythromycinThe metabolism of Efavirenz can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Efavirenz is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Efavirenz can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Efavirenz.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Efavirenz.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Efavirenz.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Efavirenz.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Efavirenz.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Efavirenz.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Efavirenz.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Efavirenz.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Efavirenz.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Efavirenz.
EthanolEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Efavirenz.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Efavirenz.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Efavirenz.
EthotoinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Efavirenz.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Efavirenz.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Efavirenz.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Efavirenz.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efavirenz.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Efavirenz.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Efavirenz.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Efavirenz.
EtodolacThe metabolism of Etodolac can be decreased when combined with Efavirenz.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Efavirenz.
EtoperidoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Efavirenz.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Efavirenz.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Efavirenz.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Efavirenz.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Efavirenz.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Efavirenz.
EzogabineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ezogabine.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Efavirenz.
FamotidineThe metabolism of Famotidine can be decreased when combined with Efavirenz.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Efavirenz.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Efavirenz.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Efavirenz.
FendilineThe serum concentration of Fendiline can be decreased when it is combined with Efavirenz.
FenfluramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fenfluramine.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Efavirenz.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Efavirenz.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efavirenz.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.
FexofenadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fexofenadine.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Efavirenz.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Efavirenz.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Efavirenz.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Efavirenz.
FluconazoleThe metabolism of Efavirenz can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Efavirenz.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Efavirenz.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Efavirenz.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Efavirenz.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Efavirenz.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Efavirenz.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Efavirenz.
FluoxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Efavirenz.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Efavirenz.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Efavirenz.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Efavirenz.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Efavirenz.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Efavirenz.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Efavirenz.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Efavirenz.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Efavirenz.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Efavirenz.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Efavirenz.
FluvoxamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fluvoxamine.
FluvoxamineThe metabolism of Efavirenz can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Efavirenz.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Efavirenz.
FosamprenavirThe metabolism of Efavirenz can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Efavirenz can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Efavirenz.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Efavirenz.
Fusidic AcidThe serum concentration of Efavirenz can be increased when it is combined with Fusidic Acid.
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Efavirenz.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Efavirenz.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Efavirenz is combined with gabapentin enacarbil.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Efavirenz.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Efavirenz.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Efavirenz.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Efavirenz.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Efavirenz.
Ginkgo bilobaThe serum concentration of Efavirenz can be decreased when it is combined with Ginkgo biloba.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Efavirenz.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Efavirenz.
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Efavirenz.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Efavirenz.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Efavirenz.
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Efavirenz.
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Efavirenz.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Efavirenz.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Efavirenz.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Efavirenz.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Efavirenz.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Efavirenz.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Efavirenz.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Efavirenz.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Efavirenz.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Efavirenz.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Efavirenz.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Efavirenz.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Efavirenz.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Efavirenz.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Efavirenz.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efavirenz.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Efavirenz.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Efavirenz.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efavirenz.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Efavirenz.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
HydroxyzineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Efavirenz.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Efavirenz.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Efavirenz.
IdelalisibThe serum concentration of Efavirenz can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Efavirenz resulting in a loss in efficacy.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Efavirenz.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Efavirenz.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Efavirenz.
ImatinibThe metabolism of Efavirenz can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Efavirenz.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Efavirenz.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Efavirenz.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Efavirenz.
IndalpineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Indalpine.
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Efavirenz.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Efavirenz.
IndinavirThe metabolism of Efavirenz can be decreased when combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Efavirenz.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Efavirenz.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Efavirenz.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Efavirenz.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Efavirenz.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Efavirenz.
IsavuconazoniumThe metabolism of Efavirenz can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Efavirenz.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Efavirenz.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Efavirenz.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Efavirenz.
IsradipineThe metabolism of Efavirenz can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Efavirenz.
ItraconazoleThe metabolism of Efavirenz can be decreased when combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Efavirenz.
IvacaftorThe serum concentration of Efavirenz can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Efavirenz.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Efavirenz.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Efavirenz.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Efavirenz.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Efavirenz.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Efavirenz.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Efavirenz.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Efavirenz.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Efavirenz.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efavirenz.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Efavirenz.
KetoconazoleThe metabolism of Efavirenz can be decreased when combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Efavirenz.
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Efavirenz.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Efavirenz.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Efavirenz.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Efavirenz.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Efavirenz.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Efavirenz.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Efavirenz.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Efavirenz.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Efavirenz.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Efavirenz.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Efavirenz.
LevetiracetamThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levetiracetam.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Efavirenz.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Efavirenz.
LevocabastineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levocabastine.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Efavirenz.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Efavirenz.
LevodopaThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levodopa.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Efavirenz.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efavirenz.
LevomilnacipranThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levomilnacipran.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Efavirenz.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efavirenz.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Efavirenz.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Efavirenz.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Efavirenz.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Efavirenz.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Efavirenz.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Efavirenz.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Efavirenz.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Efavirenz.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Efavirenz.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.
LopinavirThe metabolism of Efavirenz can be decreased when combined with Lopinavir.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Efavirenz.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Efavirenz.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Efavirenz.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Efavirenz.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Efavirenz.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Efavirenz.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Efavirenz.
LovastatinThe metabolism of Efavirenz can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.
Lu AA21004The risk or severity of adverse effects can be increased when Efavirenz is combined with Lu AA21004.
LuliconazoleThe serum concentration of Efavirenz can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Efavirenz can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Efavirenz.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Efavirenz.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Efavirenz.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Efavirenz.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Efavirenz.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Efavirenz.
ManidipineThe serum concentration of Manidipine can be decreased when it is combined with Efavirenz.
MaprotilineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Efavirenz.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Efavirenz.
MeclizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Efavirenz.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Efavirenz.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Efavirenz.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Efavirenz.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Efavirenz.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Efavirenz.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Efavirenz.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Efavirenz.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Efavirenz.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Efavirenz.
MestranolThe metabolism of Mestranol can be decreased when combined with Efavirenz.
MetaxaloneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Efavirenz.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Efavirenz.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Efavirenz.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Efavirenz.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Efavirenz.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Efavirenz.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Efavirenz.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Efavirenz.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Efavirenz.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Efavirenz.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Efavirenz.
MethsuximideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Efavirenz.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Efavirenz.
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Efavirenz.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Efavirenz.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Efavirenz.
MetyrosineEfavirenz may increase the sedative activities of Metyrosine.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Efavirenz.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Efavirenz.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Efavirenz.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Efavirenz.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Efavirenz.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Efavirenz.
MifepristoneThe serum concentration of Efavirenz can be increased when it is combined with Mifepristone.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Efavirenz.
MilnacipranThe risk or severity of adverse effects can be increased when Efavirenz is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Efavirenz.
MirtazapineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Efavirenz.
MitotaneThe serum concentration of Efavirenz can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Efavirenz.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Efavirenz.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Efavirenz.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Efavirenz.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Efavirenz.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Efavirenz.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Efavirenz.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Efavirenz.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
NabiloneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Nabilone.
NafcillinThe serum concentration of Efavirenz can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efavirenz.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Efavirenz.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Efavirenz.
NaproxenThe metabolism of Naproxen can be decreased when combined with Efavirenz.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Efavirenz.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Efavirenz.
NefazodoneThe metabolism of Efavirenz can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Efavirenz.
NelfinavirThe metabolism of Efavirenz can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Efavirenz can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Efavirenz.
NevirapineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Nevirapine.
NevirapineThe metabolism of Efavirenz can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Efavirenz.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Efavirenz.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.
NiguldipineThe serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Efavirenz.
NilotinibThe metabolism of Efavirenz can be decreased when combined with Nilotinib.
NiludipineThe serum concentration of Niludipine can be decreased when it is combined with Efavirenz.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Efavirenz.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Efavirenz.
NimesulideThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Efavirenz.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Efavirenz.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Efavirenz.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Efavirenz.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Efavirenz.
NorgestimateThe serum concentration of the active metabolites of Norgestimate can be reduced when Norgestimate is used in combination with Efavirenz resulting in a loss in efficacy.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Efavirenz.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Efavirenz.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Efavirenz.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Efavirenz.
OlanzapineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Efavirenz.
OlaparibThe metabolism of Efavirenz can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Efavirenz.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Efavirenz.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Efavirenz.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Efavirenz.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Efavirenz.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Efavirenz.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Efavirenz.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Efavirenz.
OrphenadrineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Efavirenz.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Efavirenz.
OsimertinibThe serum concentration of Efavirenz can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Efavirenz.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Efavirenz.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Efavirenz.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Efavirenz.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Efavirenz.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Efavirenz.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Efavirenz.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Efavirenz.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Efavirenz.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efavirenz.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Efavirenz.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efavirenz.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Efavirenz.
PalbociclibThe serum concentration of Efavirenz can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Efavirenz.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Efavirenz.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Efavirenz.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Efavirenz.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Efavirenz.
ParaldehydeEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Efavirenz.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Efavirenz.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Efavirenz.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Efavirenz.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Efavirenz.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Efavirenz.
ParoxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Paroxetine.
ParoxetineThe metabolism of Efavirenz can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Efavirenz.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Efavirenz.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Efavirenz.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Efavirenz.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Efavirenz.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Efavirenz.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Efavirenz.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Efavirenz.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Efavirenz.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Efavirenz.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Efavirenz.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Efavirenz.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Efavirenz.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Efavirenz.
PhenindioneThe serum concentration of Phenindione can be decreased when it is combined with Efavirenz.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Efavirenz.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Efavirenz.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Efavirenz.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Efavirenz.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Efavirenz.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Efavirenz.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Efavirenz.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Efavirenz.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Efavirenz.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Efavirenz.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Efavirenz.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Efavirenz.
PinaveriumThe serum concentration of Pinaverium can be decreased when it is combined with Efavirenz.
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Efavirenz.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Efavirenz.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Efavirenz.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Efavirenz.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Efavirenz.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Efavirenz.
PizotifenThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pizotifen.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Efavirenz.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Efavirenz.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Efavirenz.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Efavirenz.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Efavirenz.
PosaconazoleThe metabolism of Efavirenz can be decreased when combined with Posaconazole.
PramipexoleEfavirenz may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Efavirenz.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Efavirenz.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Efavirenz.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Efavirenz.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Efavirenz.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Efavirenz.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Efavirenz.
PregabalinThe serum concentration of Pregabalin can be decreased when it is combined with Efavirenz.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Efavirenz.
PrenylamineThe serum concentration of Prenylamine can be decreased when it is combined with Efavirenz.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Efavirenz.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Efavirenz.
PrimidoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Efavirenz.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Efavirenz.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Efavirenz.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Efavirenz.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Efavirenz.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Efavirenz.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Efavirenz.
PromethazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Efavirenz.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Efavirenz.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Efavirenz.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Efavirenz.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Efavirenz.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Efavirenz.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Efavirenz.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Efavirenz.
QuazepamThe serum concentration of Efavirenz can be increased when it is combined with Quazepam.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Efavirenz.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Efavirenz.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Efavirenz.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Efavirenz.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Efavirenz.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Efavirenz.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Efavirenz.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Efavirenz.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Efavirenz.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Efavirenz.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Efavirenz.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Efavirenz.
RanolazineThe metabolism of Efavirenz can be decreased when combined with Ranolazine.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Efavirenz.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Efavirenz.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efavirenz.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Efavirenz.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Efavirenz.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Efavirenz.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Efavirenz.
RifabutinThe metabolism of Efavirenz can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Efavirenz can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Efavirenz can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Efavirenz.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Efavirenz.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Efavirenz.
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Efavirenz.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Efavirenz.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Efavirenz.
RitonavirThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.
RitonavirThe metabolism of Efavirenz can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Efavirenz.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Efavirenz.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Efavirenz.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Efavirenz.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Efavirenz.
RopiniroleEfavirenz may increase the sedative activities of Ropinirole.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Efavirenz.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Efavirenz.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Efavirenz.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Efavirenz.
RotigotineEfavirenz may increase the sedative activities of Rotigotine.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Efavirenz.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Efavirenz.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Efavirenz.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Efavirenz.
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Efavirenz.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Efavirenz.
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Efavirenz.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Efavirenz.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Efavirenz.
ScopolamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Efavirenz.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Efavirenz.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Efavirenz.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Efavirenz.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Efavirenz.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Efavirenz.
SertralineThe metabolism of Efavirenz can be decreased when combined with Sertraline.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Efavirenz.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Efavirenz.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Efavirenz.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Efavirenz.
SildenafilThe metabolism of Efavirenz can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Efavirenz.
SiltuximabThe serum concentration of Efavirenz can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Efavirenz can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Efavirenz.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Efavirenz.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Efavirenz.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Efavirenz.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Efavirenz.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Efavirenz.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Efavirenz.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Efavirenz.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Efavirenz.
SorafenibThe metabolism of Efavirenz can be decreased when combined with Sorafenib.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Efavirenz.
St. John's WortThe serum concentration of Efavirenz can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Efavirenz is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Efavirenz.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efavirenz.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Efavirenz.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Efavirenz.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Efavirenz.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Efavirenz.
SulfisoxazoleThe metabolism of Efavirenz can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Efavirenz.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Efavirenz.
SuprofenThe metabolism of Suprofen can be decreased when combined with Efavirenz.
SuvorexantThe risk or severity of adverse effects can be increased when Efavirenz is combined with Suvorexant.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Efavirenz.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Efavirenz.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Efavirenz.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Efavirenz.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Efavirenz.
TapentadolThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tasimelteon.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Efavirenz.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Efavirenz.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Efavirenz.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Efavirenz.
TelaprevirThe metabolism of Efavirenz can be decreased when combined with Telaprevir.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Efavirenz.
TelithromycinThe metabolism of Efavirenz can be decreased when combined with Telithromycin.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Efavirenz.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Efavirenz.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Efavirenz.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Efavirenz.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Efavirenz.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Efavirenz.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Efavirenz.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Efavirenz.
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Efavirenz.
TetrabenazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Efavirenz.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Efavirenz.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Efavirenz.
ThalidomideEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Efavirenz.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Efavirenz.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Efavirenz.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Efavirenz.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Efavirenz.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Efavirenz.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Efavirenz.
ThiotepaThe metabolism of Efavirenz can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Efavirenz.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Efavirenz.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Efavirenz.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Efavirenz.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Efavirenz.
TiclopidineThe metabolism of Efavirenz can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Efavirenz.
TimololThe metabolism of Timolol can be decreased when combined with Efavirenz.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Efavirenz.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Efavirenz.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Efavirenz.
TizanidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.
TocilizumabThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Efavirenz.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Efavirenz.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Efavirenz.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Efavirenz.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Efavirenz.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.
TorasemideThe metabolism of Torasemide can be decreased when combined with Efavirenz.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Efavirenz.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Efavirenz.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Efavirenz.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Efavirenz.
TranilastThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Efavirenz.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Efavirenz.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Efavirenz.
TrazodoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Trazodone.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Efavirenz.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Efavirenz.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Efavirenz.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Efavirenz.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Efavirenz.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Efavirenz.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Efavirenz.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Efavirenz.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Efavirenz.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Efavirenz.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Efavirenz.
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Efavirenz.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Efavirenz.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Efavirenz.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Efavirenz.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Efavirenz.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Efavirenz.
ValsartanThe metabolism of Valsartan can be decreased when combined with Efavirenz.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Efavirenz.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Efavirenz.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Efavirenz.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Efavirenz.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Efavirenz.
VenlafaxineThe metabolism of Efavirenz can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.
VerapamilThe metabolism of Efavirenz can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Efavirenz.
VigabatrinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vigabatrin.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Efavirenz.
VilazodoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Efavirenz.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Efavirenz.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Efavirenz.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Efavirenz.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Efavirenz.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Efavirenz.
VoriconazoleThe metabolism of Efavirenz can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vortioxetine.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Efavirenz.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Efavirenz.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Efavirenz.
XylometazolineThe serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Efavirenz.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Efavirenz.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Efavirenz.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Efavirenz.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Efavirenz.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Efavirenz.
ZiconotideThe serum concentration of Ziconotide can be decreased when it is combined with Efavirenz.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Efavirenz.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Efavirenz.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Efavirenz.
ZimelidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zimelidine.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Efavirenz.
ZiprasidoneThe metabolism of Efavirenz can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Efavirenz.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Efavirenz.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Efavirenz.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Efavirenz.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Efavirenz.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Efavirenz.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Efavirenz.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Efavirenz.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Efavirenz.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Efavirenz.
Food Interactions
  • Avoid excessive or chronic alcohol consumption.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna-dna hybrid ribonuclease activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72547
Molecular Weight:
65223.615 Da
References
  1. Gazzard BG: Efavirenz in the management of HIV infection. Int J Clin Pract. 1999 Jan-Feb;53(1):60-4. [PubMed:10344069 ]
  2. Adkins JC, Noble S: Efavirenz. Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. [PubMed:9878993 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100-2. [PubMed:11159797 ]
  3. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 03:41